NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Domain Therapeutics

Domain Therapeutics

Private
MontrealHealthcare & Life Scienceshttps://www.kainovatx.com/en/

Last Round

Series B

Feb 10, 2026

Total Funding Raised

$72.91M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Kainova Therapeutics is a biopharmaceutical company that develops breakthrough therapies targeting G protein-coupled receptors (GPCRs) for the treatment of immuno-oncology and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

GPCRG protein-coupled receptorsdrug discoverysmall molecule therapybiotechbioSens-Alldrug discovery platformclinical-stage biopharmadrug pipelineinflammatory diseaseoncologydrug licensingBRET biosensorspharma partnershipundruggable targets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Domain Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Domain Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Domain Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 10, 2026
GrantJan 25, 2024
Series AMay 10, 2022
GrantJan 27, 2022
DebtJan 13, 2020
VC Round
May 28, 2019

Key People

Founding team and executive leadership

Stanislas MALMEZAT

Chief Financial Officer - CFO - Biotech Drug discovery Clinical development

Executive Team

Domain Therapeutics Investors

Notable investors and investment history

Domain Therapeutics investors
InvestorRounds
Investissement QuébecSeries B
Idinvest PartnersVC Round
CTI Life Sciences FundSeries B, Series A
Alsace Inter Regio Fonds d’InvestissementVC Round
Andera PartnersVC Round
Agence Nationale de la RechercheGrant
3B FUTURE Health FundSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 10, 2026

    $24M round led by Investissement Québec

  • Nov 13, 2025

    Jean-Marie Cuillerot, M.D. appointed as new CMO.

Domain Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Domain Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Domain Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMontreal
Employee Range36
Year Founded2008
Last FundingFeb 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.